{"id":3545,"date":"2021-05-14T14:29:55","date_gmt":"2021-05-14T11:29:55","guid":{"rendered":"https:\/\/info.e-med.co.il\/remsima\/?p=3545"},"modified":"2023-10-25T14:48:41","modified_gmt":"2023-10-25T11:48:41","slug":"efficacy-pharmacokinetics-and-safety-of-subcutaneous-versus-intravenous-ct-p13-in-rheumatoid-arthritis-a-randomized-phase-i-iii-trial","status":"publish","type":"post","link":"https:\/\/info.e-med.co.il\/remsima\/efficacy-pharmacokinetics-and-safety-of-subcutaneous-versus-intravenous-ct-p13-in-rheumatoid-arthritis-a-randomized-phase-i-iii-trial\/","title":{"rendered":"Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial"},"content":{"rendered":"

Abstract<\/h3>\n
\n

Objective:\u00a0<\/strong>To assess non-inferiority of s.c. to i.v. CT-P13 in RA.<\/p>\n

Methods:\u00a0<\/strong>Patients with active RA and inadequate response to MTX participated in this phase I\/III double-blind study at 76 sites. Patients received CT-P13 i.v. 3 mg\/kg [week (W) 0 and W2] before randomization (1:1) at W6 to CT-P13 s.c. via pre-filled syringe (PFS) 120 mg biweekly until W28, or CT-P13 i.v. 3 mg\/kg every 8 weeks until W22. Randomization was stratified by country, W2 serum CRP and W6 body weight.<\/p>\n

\u05dc\u05d4\u05de\u05e9\u05da \u05e7\u05e8\u05d9\u05d0\u05d4<\/a><\/strong><\/p>\n<\/div>\n

Westhovens R, Wiland P, Zawadzki M, Ivanova D, Kasay AB, El-Khouri EC, Bal\u00e1zs \u00c9, Shevchuk S, Eliseeva L, Stanislavchuk M, Yatsyshyn R, Hrycaj P, Jaworski J, Zhdan V, Trefler J, Shesternya P, Lee SJ, Kim SH, Suh JH, Lee SG, Han NR, Yoo DH. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial. Rheumatology (Oxford). 2021 May 14;60(5):2277-2287. doi: 10.1093\/rheumatology\/keaa580. PMID: 33230526; PMCID: PMC8121438.<\/p>\n","protected":false},"excerpt":{"rendered":"

Westhovens et.al.; Rheumatology 2021;60:2277\u20132287 <\/strong><\/p>\n","protected":false},"author":2,"featured_media":3546,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"footnotes":""},"categories":[28,26,24],"tags":[],"class_list":["post-3545","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-article-en","category-research","category-updates-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t